COVID-19 and thrombosis: Prophylaxis and management
| Autor: | Bengü Şaylan, Kadir Canoglu, Tayfun Çalışkan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty ARDS Turkey medicine.drug_class Low molecular weight heparin Disease Critical Care and Intensive Care Medicine Asymptomatic Pandemic medicine Coagulopathy Humans Disease management (health) Intensive care medicine Pandemics SARS-CoV-2 business.industry Anticoagulants COVID-19 Disease Management Venous Thromboembolism medicine.disease Thrombosis Surgery medicine.symptom business |
| Zdroj: | Tuberk Toraks. 69:269-278 |
| ISSN: | 0494-1373 |
| DOI: | 10.5578/tt.20219818 |
| Popis: | COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a pandemic on March 11, 2020. The disease has a wide spectrum ranging from asymptomatic or mild disease to ARDS and death. There have been over 83.9 million cases with 1.8 million deaths worldwide. COVIDassociated coagulopathy appears to be an entity responsible for deaths. Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism. Low molecular weight heparin such as enoxaparin is often recommended. However, there is still no consensus regarding the treatment dose and duration. The purpose of this review was to observe the pathogenesis of thromboembolic events in COVID-19, current thromboprophylaxis regimens, treatment dosage and duration with guidelines of international scientific institutions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|